MAPT and Cognitive impairment: The tau aggregation inhibitor, TRx0237 (HMTM/LMTX/LMTM/methylthioninium chloride), is being developed by TauRx Therapeutics Ltd, for AD dementia and Mild Cognitive Impairment (MCI).